APO Research
Talk to an analyst

APO RESEARCH · REPORT

Poxviridae Infections Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Poxviridae Infections Drug Industry Growth and Trends Forecast to 2032

26 December 2025108 pages

Choose your research edition.

Industry ResearchPoxviridae Infections Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Poxviridae Infections Drug Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Poxviridae Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Poxviridae Infections Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Poxviridae Infections Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Poxviridae Infections Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Poxviridae Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Poxviridae Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Poxviridae Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Poxviridae Infections Drug include Takeda Pharmaceutical Company Limited, China Biologic Products, Inc., Verrica Pharmaceuticals Inc., Tonix Pharmaceuticals Holding Corp., SIGA Technologies, Inc., N & N Pharmaceuticals Inc., EpiVax, Inc., CJ HealthCare Corp. and Chimerix, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Poxviridae Infections Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Poxviridae Infections Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Poxviridae Infections Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Poxviridae Infections Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Poxviridae Infections Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Poxviridae Infections Drug Market by Company

Takeda Pharmaceutical Company Limited

China Biologic Products, Inc.

Verrica Pharmaceuticals Inc.

Tonix Pharmaceuticals Holding Corp.

SIGA Technologies, Inc.

N & N Pharmaceuticals Inc.

EpiVax, Inc.

CJ HealthCare Corp.

Chimerix, Inc.

CEL-SCI Corporation

BioFactura, Inc.

Bavarian Nordic A/S

Poxviridae Infections Drug Segment by Type

CJ-40011

BA-368

24a

Others

Poxviridae Infections Drug Segment by Application

Hospital

Clinic

Others

Poxviridae Infections Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Poxviridae Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Poxviridae Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Poxviridae Infections Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Poxviridae Infections Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Poxviridae Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of CJ-40011 Table 2. Major Company of BA-368 Table 3. Major Company of 24a Table 4. Major Company of Others Table 5. Global Poxviridae Infections Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 7. Global Poxviridae Infections Drug Sales Market Share in Volume by Type (2021-2026) Table 8. Global Poxviridae Infections Drug Sales by Type (2021-2026) & (US$ Million) Table 9. Global Poxviridae Infections Drug Sales Market Share in Value by Type (2021-2026) Table 10. Global Poxviridae Infections Drug Price by Type (2021-2026) & (US$/Unit) Table 11. Global Poxviridae Infections Drug Sales by Type (2027-2032) & (K Units) Table 12. Global Poxviridae Infections Drug Sales Market Share in Volume by Type (2027-2032) Table 13. Global Poxviridae Infections Drug Sales by Type (2027-2032) & (US$ Million) Table 14. Global Poxviridae Infections Drug Sales Market Share in Value by Type (2027-2032) Table 15. Global Poxviridae Infections Drug Price by Type (2027-2032) & (US$/Unit) Table 16. North America Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 17. North America Poxviridae Infections Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 19. Europe Poxviridae Infections Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Poxviridae Infections Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 23. Latin America Poxviridae Infections Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Poxviridae Infections Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Poxviridae Infections Drug Industry Trends Table 27. Poxviridae Infections Drug Industry Drivers Table 28. Poxviridae Infections Drug Industry Opportunities and Challenges Table 29. Poxviridae Infections Drug Industry Restraints Table 30. Global Poxviridae Infections Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Poxviridae Infections Drug Revenue Market Share by Company (2021-2026) Table 32. Global Poxviridae Infections Drug Sales by Company (2021-2026) & (K Units) Table 33. Global Poxviridae Infections Drug Sales Share by Company (2021-2026) Table 34. Global Poxviridae Infections Drug Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Poxviridae Infections Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Poxviridae Infections Drug Major Company Production Sites and Headquarters Table 37. Global Poxviridae Infections Drug Company, Product Type & Application Table 38. Global Poxviridae Infections Drug Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Poxviridae Infections Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Poxviridae Infections Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Poxviridae Infections Drug Sales by Region (2021-2026) & (K Units) Table 43. Global Poxviridae Infections Drug Sales Market Share in Volume by Region (2021-2026) Table 44. Global Poxviridae Infections Drug Sales by Region (2021-2026) & (US$ Million) Table 45. Global Poxviridae Infections Drug Sales Market Share in Value by Region (2021-2026) Table 46. Global Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Poxviridae Infections Drug Sales by Region (2027-2032) & (K Units) Table 48. Global Poxviridae Infections Drug Sales Market Share in Volume by Region (2027-2032) Table 49. Global Poxviridae Infections Drug Sales by Region (2027-2032) & (US$ Million) Table 50. Global Poxviridae Infections Drug Sales Market Share in Value by Region (2027-2032) Table 51. Global Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Poxviridae Infections Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 54. Global Poxviridae Infections Drug Sales Market Share in Volume by Application (2021-2026) Table 55. Global Poxviridae Infections Drug Sales by Application (2021-2026) & (US$ Million) Table 56. Global Poxviridae Infections Drug Sales Market Share in Value by Application (2021-2026) Table 57. Global Poxviridae Infections Drug Price by Application (2021-2026) & (US$/Unit) Table 58. Global Poxviridae Infections Drug Sales by Application (2027-2032) & (K Units) Table 59. Global Poxviridae Infections Drug Sales Market Share in Volume by Application (2027-2032) Table 60. Global Poxviridae Infections Drug Sales by Application (2027-2032) & (US$ Million) Table 61. Global Poxviridae Infections Drug Sales Market Share in Value by Application (2027-2032) Table 62. Global Poxviridae Infections Drug Price by Application (2027-2032) & (US$/Unit) Table 63. North America Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 64. North America Poxviridae Infections Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 66. Europe Poxviridae Infections Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Poxviridae Infections Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 70. Latin America Poxviridae Infections Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Poxviridae Infections Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Takeda Pharmaceutical Company Limited Company Information Table 74. Takeda Pharmaceutical Company Limited Business Overview Table 75. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Portfolio Table 77. Takeda Pharmaceutical Company Limited Recent Development Table 78. China Biologic Products, Inc. Company Information Table 79. China Biologic Products, Inc. Business Overview Table 80. China Biologic Products, Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. China Biologic Products, Inc. Poxviridae Infections Drug Product Portfolio Table 82. China Biologic Products, Inc. Recent Development Table 83. Verrica Pharmaceuticals Inc. Company Information Table 84. Verrica Pharmaceuticals Inc. Business Overview Table 85. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio Table 87. Verrica Pharmaceuticals Inc. Recent Development Table 88. Tonix Pharmaceuticals Holding Corp. Company Information Table 89. Tonix Pharmaceuticals Holding Corp. Business Overview Table 90. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Portfolio Table 92. Tonix Pharmaceuticals Holding Corp. Recent Development Table 93. SIGA Technologies, Inc. Company Information Table 94. SIGA Technologies, Inc. Business Overview Table 95. SIGA Technologies, Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. SIGA Technologies, Inc. Poxviridae Infections Drug Product Portfolio Table 97. SIGA Technologies, Inc. Recent Development Table 98. N & N Pharmaceuticals Inc. Company Information Table 99. N & N Pharmaceuticals Inc. Business Overview Table 100. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio Table 102. N & N Pharmaceuticals Inc. Recent Development Table 103. EpiVax, Inc. Company Information Table 104. EpiVax, Inc. Business Overview Table 105. EpiVax, Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. EpiVax, Inc. Poxviridae Infections Drug Product Portfolio Table 107. EpiVax, Inc. Recent Development Table 108. CJ HealthCare Corp. Company Information Table 109. CJ HealthCare Corp. Business Overview Table 110. CJ HealthCare Corp. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. CJ HealthCare Corp. Poxviridae Infections Drug Product Portfolio Table 112. CJ HealthCare Corp. Recent Development Table 113. Chimerix, Inc. Company Information Table 114. Chimerix, Inc. Business Overview Table 115. Chimerix, Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Chimerix, Inc. Poxviridae Infections Drug Product Portfolio Table 117. Chimerix, Inc. Recent Development Table 118. CEL-SCI Corporation Company Information Table 119. CEL-SCI Corporation Business Overview Table 120. CEL-SCI Corporation Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. CEL-SCI Corporation Poxviridae Infections Drug Product Portfolio Table 122. CEL-SCI Corporation Recent Development Table 123. BioFactura, Inc. Company Information Table 124. BioFactura, Inc. Business Overview Table 125. BioFactura, Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. BioFactura, Inc. Poxviridae Infections Drug Product Portfolio Table 127. BioFactura, Inc. Recent Development Table 128. Bavarian Nordic A/S Company Information Table 129. Bavarian Nordic A/S Business Overview Table 130. Bavarian Nordic A/S Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Bavarian Nordic A/S Poxviridae Infections Drug Product Portfolio Table 132. Bavarian Nordic A/S Recent Development Table 133. North America Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 134. North America Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 135. North America Poxviridae Infections Drug Sales Market Share by Country (2021-2026) Table 136. North America Poxviridae Infections Drug Sales Forecast by Country (2027-2032) & (K Units) Table 137. North America Poxviridae Infections Drug Sales Market Share Forecast by Country (2027-2032) Table 138. North America Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. North America Poxviridae Infections Drug Market Size by Country (2021-2026) & (US$ Million) Table 140. North America Poxviridae Infections Drug Market Share by Country (2021-2026) Table 141. North America Poxviridae Infections Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. North America Poxviridae Infections Drug Market Share Forecast by Country (2027-2032) Table 143. Europe Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 144. Europe Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 145. Europe Poxviridae Infections Drug Sales Market Share by Country (2021-2026) Table 146. Europe Poxviridae Infections Drug Sales Forecast by Country (2027-2032) & (K Units) Table 147. Europe Poxviridae Infections Drug Sales Market Share Forecast by Country (2027-2032) Table 148. Europe Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Europe Poxviridae Infections Drug Market Size by Country (2021-2026) & (US$ Million) Table 150. Europe Poxviridae Infections Drug Market Share by Country (2021-2026) Table 151. Europe Poxviridae Infections Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Europe Poxviridae Infections Drug Market Share Forecast by Country (2027-2032) Table 153. Asia-Pacific Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 154. Asia-Pacific Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 155. Asia-Pacific Poxviridae Infections Drug Sales Market Share by Country (2021-2026) Table 156. Asia-Pacific Poxviridae Infections Drug Sales Forecast by Country (2027-2032) & (K Units) Table 157. Asia-Pacific Poxviridae Infections Drug Sales Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Poxviridae Infections Drug Market Size by Country (2021-2026) & (US$ Million) Table 160. Asia-Pacific Poxviridae Infections Drug Market Share by Country (2021-2026) Table 161. Asia-Pacific Poxviridae Infections Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Asia-Pacific Poxviridae Infections Drug Market Share Forecast by Country (2027-2032) Table 163. Latin America Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 164. Latin America Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 165. Latin America Poxviridae Infections Drug Sales Market Share by Country (2021-2026) Table 166. Latin America Poxviridae Infections Drug Sales Forecast by Country (2027-2032) & (K Units) Table 167. Latin America Poxviridae Infections Drug Sales Market Share Forecast by Country (2027-2032) Table 168. Latin America Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Latin America Poxviridae Infections Drug Market Size by Country (2021-2026) & (US$ Million) Table 170. Latin America Poxviridae Infections Drug Market Share by Country (2021-2026) Table 171. Latin America Poxviridae Infections Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Latin America Poxviridae Infections Drug Market Share Forecast by Country (2027-2032) Table 173. Middle East and Africa Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 174. Middle East and Africa Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 175. Middle East and Africa Poxviridae Infections Drug Sales Market Share by Country (2021-2026) Table 176. Middle East and Africa Poxviridae Infections Drug Sales Forecast by Country (2027-2032) & (K Units) Table 177. Middle East and Africa Poxviridae Infections Drug Sales Market Share Forecast by Country (2027-2032) Table 178. Middle East and Africa Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Middle East and Africa Poxviridae Infections Drug Market Size by Country (2021-2026) & (US$ Million) Table 180. Middle East and Africa Poxviridae Infections Drug Market Share by Country (2021-2026) Table 181. Middle East and Africa Poxviridae Infections Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Middle East and Africa Poxviridae Infections Drug Market Share Forecast by Country (2027-2032) Table 183. Key Raw Materials Table 184. Raw Materials Key Suppliers Table 185. Poxviridae Infections Drug Distributors List Table 186. Poxviridae Infections Drug Customers List Table 187. Research Programs/Design for This Report Table 188. Authors List of This Report Table 189. Secondary Sources Table 190. Primary Sources List of Figures Figure 1. Poxviridae Infections Drug Image Figure 2. Global Poxviridae Infections Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Poxviridae Infections Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Poxviridae Infections Drug Sales (2021-2032) & (K Units) Figure 5. CJ-40011 Image Figure 6. Global CJ-40011 Sales YoY Growth (2021-2032) & (K Units) Figure 7. BA-368 Image Figure 8. Global BA-368 Sales YoY Growth (2021-2032) & (K Units) Figure 9. 24a Image Figure 10. Global 24a Sales YoY Growth (2021-2032) & (K Units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Poxviridae Infections Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Poxviridae Infections Drug Market Share by Type 2025 VS 2032 Figure 15. North America Poxviridae Infections Drug Sales Market Share in Volume by Type in 2025 Figure 16. North America Poxviridae Infections Drug Sales Market Share in Value by Type in 2025 Figure 17. Europe Poxviridae Infections Drug Sales Market Share in Volume by Type in 2025 Figure 18. Europe Poxviridae Infections Drug Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Poxviridae Infections Drug Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Poxviridae Infections Drug Sales Market Share in Value by Type in 2025 Figure 21. Latin America Poxviridae Infections Drug Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Poxviridae Infections Drug Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Poxviridae Infections Drug Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Poxviridae Infections Drug Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Poxviridae Infections Drug Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital Image Figure 28. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Poxviridae Infections Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Poxviridae Infections Drug Market Share by Application 2025 VS 2032 Figure 35. North America Poxviridae Infections Drug Sales Market Share in Volume by Application in 2025 Figure 36. North America Poxviridae Infections Drug Sales Market Share in Value by Application in 2025 Figure 37. Europe Poxviridae Infections Drug Sales Market Share in Volume by Application in 2025 Figure 38. Europe Poxviridae Infections Drug Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Poxviridae Infections Drug Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Poxviridae Infections Drug Sales Market Share in Value by Application in 2025 Figure 41. Latin America Poxviridae Infections Drug Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Poxviridae Infections Drug Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Poxviridae Infections Drug Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Poxviridae Infections Drug Sales Market Share in Value by Application in 2025 Figure 45. North America Poxviridae Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Poxviridae Infections Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Poxviridae Infections Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Poxviridae Infections Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Poxviridae Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Poxviridae Infections Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Poxviridae Infections Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Poxviridae Infections Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Poxviridae Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Poxviridae Infections Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Poxviridae Infections Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Poxviridae Infections Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Poxviridae Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Poxviridae Infections Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Poxviridae Infections Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Poxviridae Infections Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Poxviridae Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Poxviridae Infections Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Poxviridae Infections Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Poxviridae Infections Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Poxviridae Infections Drug Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Poxviridae Infections Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • CJ-40011
  • BA-368
  • 24a
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Takeda Pharmaceutical Company Limited
  • China Biologic Products, Inc.
  • Verrica Pharmaceuticals Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • SIGA Technologies, Inc.
  • N & N Pharmaceuticals Inc.
  • EpiVax, Inc.
  • CJ HealthCare Corp.
  • Chimerix, Inc.
  • CEL-SCI Corporation
  • BioFactura, Inc.
  • Bavarian Nordic A/S

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Poxviridae Infections Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Poxviridae Infections Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Poxviridae Infections Drug Market by Type
  6. 1.3.1 CJ-40011
  7. 1.3.2 BA-368
  8. 1.3.3 24a
  9. 1.3.4 Others
  10. 1.4 Global Poxviridae Infections Drug Market Size by Type
  11. 1.4.1 Global Poxviridae Infections Drug Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Poxviridae Infections Drug Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Poxviridae Infections Drug Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Poxviridae Infections Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Poxviridae Infections Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Poxviridae Infections Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Poxviridae Infections Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Poxviridae Infections Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Poxviridae Infections Drug Industry Trends
  2. 2.2 Poxviridae Infections Drug Industry Drivers
  3. 2.3 Poxviridae Infections Drug Industry Opportunities and Challenges
  4. 2.4 Poxviridae Infections Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Poxviridae Infections Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Poxviridae Infections Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Poxviridae Infections Drug Price (2021-2026)
  4. 3.4 Global Poxviridae Infections Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Poxviridae Infections Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Poxviridae Infections Drug Company, Product Type & Application
  7. 3.7 Global Poxviridae Infections Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Poxviridae Infections Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Poxviridae Infections Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Poxviridae Infections Drug Tier 1, Tier 2, and Tier 3
4 Poxviridae Infections Drug Regional Status and Outlook
  1. 4.1 Global Poxviridae Infections Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Poxviridae Infections Drug Historic Market Size by Region
  3. 4.2.1 Global Poxviridae Infections Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Poxviridae Infections Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Poxviridae Infections Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Poxviridae Infections Drug Forecasted Market Size by Region
  7. 4.3.1 Global Poxviridae Infections Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Poxviridae Infections Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Poxviridae Infections Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Poxviridae Infections Drug by Application
  1. 5.1 Poxviridae Infections Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Poxviridae Infections Drug Market Size by Application
  6. 5.2.1 Global Poxviridae Infections Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Poxviridae Infections Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Poxviridae Infections Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Poxviridae Infections Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Poxviridae Infections Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Poxviridae Infections Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Poxviridae Infections Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Poxviridae Infections Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda Pharmaceutical Company Limited
  2. 6.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 6.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 6.1.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Portfolio
  6. 6.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 6.2 China Biologic Products, Inc.
  8. 6.2.1 China Biologic Products, Inc. Company Information
  9. 6.2.2 China Biologic Products, Inc. Business Overview
  10. 6.2.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 China Biologic Products, Inc. Poxviridae Infections Drug Product Portfolio
  12. 6.2.5 China Biologic Products, Inc. Recent Developments
  13. 6.3 Verrica Pharmaceuticals Inc.
  14. 6.3.1 Verrica Pharmaceuticals Inc. Company Information
  15. 6.3.2 Verrica Pharmaceuticals Inc. Business Overview
  16. 6.3.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio
  18. 6.3.5 Verrica Pharmaceuticals Inc. Recent Developments
  19. 6.4 Tonix Pharmaceuticals Holding Corp.
  20. 6.4.1 Tonix Pharmaceuticals Holding Corp. Company Information
  21. 6.4.2 Tonix Pharmaceuticals Holding Corp. Business Overview
  22. 6.4.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Portfolio
  24. 6.4.5 Tonix Pharmaceuticals Holding Corp. Recent Developments
  25. 6.5 SIGA Technologies, Inc.
  26. 6.5.1 SIGA Technologies, Inc. Company Information
  27. 6.5.2 SIGA Technologies, Inc. Business Overview
  28. 6.5.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 SIGA Technologies, Inc. Poxviridae Infections Drug Product Portfolio
  30. 6.5.5 SIGA Technologies, Inc. Recent Developments
  31. 6.6 N & N Pharmaceuticals Inc.
  32. 6.6.1 N & N Pharmaceuticals Inc. Company Information
  33. 6.6.2 N & N Pharmaceuticals Inc. Business Overview
  34. 6.6.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio
  36. 6.6.5 N & N Pharmaceuticals Inc. Recent Developments
  37. 6.7 EpiVax, Inc.
  38. 6.7.1 EpiVax, Inc. Company Information
  39. 6.7.2 EpiVax, Inc. Business Overview
  40. 6.7.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 EpiVax, Inc. Poxviridae Infections Drug Product Portfolio
  42. 6.7.5 EpiVax, Inc. Recent Developments
  43. 6.8 CJ HealthCare Corp.
  44. 6.8.1 CJ HealthCare Corp. Company Information
  45. 6.8.2 CJ HealthCare Corp. Business Overview
  46. 6.8.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 CJ HealthCare Corp. Poxviridae Infections Drug Product Portfolio
  48. 6.8.5 CJ HealthCare Corp. Recent Developments
  49. 6.9 Chimerix, Inc.
  50. 6.9.1 Chimerix, Inc. Company Information
  51. 6.9.2 Chimerix, Inc. Business Overview
  52. 6.9.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Chimerix, Inc. Poxviridae Infections Drug Product Portfolio
  54. 6.9.5 Chimerix, Inc. Recent Developments
  55. 6.10 CEL-SCI Corporation
  56. 6.10.1 CEL-SCI Corporation Company Information
  57. 6.10.2 CEL-SCI Corporation Business Overview
  58. 6.10.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 CEL-SCI Corporation Poxviridae Infections Drug Product Portfolio
  60. 6.10.5 CEL-SCI Corporation Recent Developments
  61. 6.11 BioFactura, Inc.
  62. 6.11.1 BioFactura, Inc. Company Information
  63. 6.11.2 BioFactura, Inc. Business Overview
  64. 6.11.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 BioFactura, Inc. Poxviridae Infections Drug Product Portfolio
  66. 6.11.5 BioFactura, Inc. Recent Developments
  67. 6.12 Bavarian Nordic A/S
  68. 6.12.1 Bavarian Nordic A/S Company Information
  69. 6.12.2 Bavarian Nordic A/S Business Overview
  70. 6.12.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Bavarian Nordic A/S Poxviridae Infections Drug Product Portfolio
  72. 6.12.5 Bavarian Nordic A/S Recent Developments
7 North America by Country
  1. 7.1 North America Poxviridae Infections Drug Sales by Country
  2. 7.1.1 North America Poxviridae Infections Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Poxviridae Infections Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Poxviridae Infections Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Poxviridae Infections Drug Market Size by Country
  6. 7.2.1 North America Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Poxviridae Infections Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Poxviridae Infections Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Poxviridae Infections Drug Sales by Country
  2. 8.1.1 Europe Poxviridae Infections Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Poxviridae Infections Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Poxviridae Infections Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Poxviridae Infections Drug Market Size by Country
  6. 8.2.1 Europe Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Poxviridae Infections Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Poxviridae Infections Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Poxviridae Infections Drug Sales by Country
  2. 9.1.1 Asia-Pacific Poxviridae Infections Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Poxviridae Infections Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Poxviridae Infections Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Poxviridae Infections Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Poxviridae Infections Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Poxviridae Infections Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Poxviridae Infections Drug Sales by Country
  2. 10.1.1 South America Poxviridae Infections Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Poxviridae Infections Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Poxviridae Infections Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Poxviridae Infections Drug Market Size by Country
  6. 10.2.1 South America Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Poxviridae Infections Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Poxviridae Infections Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Poxviridae Infections Drug Sales by Country
  2. 11.1.1 Middle East and Africa Poxviridae Infections Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Poxviridae Infections Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Poxviridae Infections Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Poxviridae Infections Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Poxviridae Infections Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Poxviridae Infections Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Poxviridae Infections Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Poxviridae Infections Drug Value Chain Analysis
  2. 12.1.1 Poxviridae Infections Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Poxviridae Infections Drug Production Mode & Process
  7. 12.2 Poxviridae Infections Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Poxviridae Infections Drug Distributors
  10. 12.2.3 Poxviridae Infections Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst